Previsioni di mercato dei servizi di farmacocinetica nell\'Asia Pacifica fino al 2031 - Analisi regionale - per tipo di farmaco (piccole molecole, grandi molecole e vaccini), tipo di servizio (studi ADME e umani preclinici, analisi e reporting PK/PD, simulazioni di dosaggio, analisi del rischio e altri), applicazione terapeutica (oncologia, malattie infettive, disturbi neurologici, malattie autoimmuni, disturbi ginecologici, malattie cardiovascolari, disturbi respiratori e altri) e utente finale (aziende farmaceutiche e biotecnologiche, organizzazioni di ricerca a contratto e altri)

BMIRE00030886 | Pages: 95 | Pharmaceuticals | Oct 2024 | Type: Regional | Status: Published
Il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è stato valutato a 191,44 milioni di dollari nel 2023 e si prevede che raggiungerà i 356,58 milioni di dollari entro il 2031; si stima che registrerà un CAGR dell\'8,1% dal 2023 al 2031.

La crescente adozione di modelli in vivo e in vitro per comprendere la variabilità nella farmacocinetica potenzia il mercato dei servizi di farmacocinetica dell\'Asia Pacifica

La raccolta e la gestione di enormi dati farmacocinetici generati durante la produzione di farmaci sono attività costose, noiose e che richiedono molto tempo. La natura laboriosa e costosa di queste attività evidenzia la necessità di modelli come modelli di simulazione farmacocinetica e modelli di correlazione farmacocinetica in vitro-in vivo (IVIVC) per la previsione dei parametri farmacocinetici. Il modello di simulazione farmacocinetica è uno strumento che interpreta la cinetica dei farmaci nell\'ambiente di vita in condizioni specifiche utilizzando modelli computazionali e matematici. Inoltre, il modello IVIVC è una parte fondamentale del processo di scoperta dei farmaci. L\'analisi delle previsioni PK/PD nelle fasi iniziali dello sviluppo dei farmaci è necessaria per le strategie di ottimizzazione dei lead e anche per ridurre ulteriormente i tassi di abbandono. Ci sono stati progressi significativi nello sviluppo di nuove strategie in vitro e in vivo per migliorare e caratterizzare le proprietà farmacocinetiche. I modelli IVIVC vengono proposti come un\'alternativa conveniente per valutare le proprietà biofarmaceutiche che analizzano la biodisponibilità dei farmaci e la loro applicazione. Pertanto, si prevede che tali modelli in vivo e in vitro forniranno opportunità redditizie per il mercato dei servizi di farmacocinetica dell\'Asia Pacifica nel prossimo futuro.

Panoramica del mercato dei servizi di farmacocinetica dell\'Asia Pacifica

La crescita del mercato dei servizi di farmacocinetica dell\'Asia Pacifica in Cina è attribuita principalmente al mercato farmaceutico consolidato, all\'aumento delle spese di ricerca e sviluppo da parte delle aziende farmaceutiche e biofarmaceutiche, all\'aumento del numero di sperimentazioni cliniche dovuto ai minori costi operativi e alle favorevoli politiche normative in atto. Secondo il rapporto EFPIA pubblicato nel 2023, la spesa in R&S delle aziende farmaceutiche in Cina è cresciuta da 10.814,23 milioni di dollari nel 2020 a 12.989,23 milioni di dollari nel 2021. La Cina ha il secondo mercato farmaceutico più grande al mondo. L\'eccessiva popolazione nel paese, unita all\'aumento dei casi di varie malattie non trasmissibili e infettive, alimenta la necessità di nuove molecole farmacologiche, il che rende la Cina un mercato primario nell\'Asia Pacifica.

Fatturato e previsioni del mercato dei servizi di farmacocinetica dell\'Asia Pacifica fino al 2031 (milioni di dollari USA)

Segmentazione del mercato dei servizi di farmacocinetica dell\'Asia Pacifica

Il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è suddiviso in tipo di farmaco, tipo di servizio, applicazione terapeutica, utente finale e paese.

In base al tipo di farmaco, il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è suddiviso in piccole molecole, grandi molecole e vaccini. Il segmento delle piccole molecole ha detenuto la quota di mercato più ampia nel 2023.

In termini di tipo di servizio, il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è suddiviso in ADME preclinico e studi sull\'uomo, analisi e reporting PK/PD, simulazioni di dosaggio, analisi del rischio e altri. Il segmento ADME preclinico e studi sull\'uomo ha detenuto la quota di mercato più ampia nel 2023.

In base all\'applicazione terapeutica, il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è suddiviso in oncologia, malattie infettive, disturbi neurologici, malattie autoimmuni, disturbi ginecologici, malattie cardiovascolari, disturbi respiratori e altri. Il segmento oncologico ha detenuto la quota di mercato più ampia nel 2023.

In base all\'utente finale, il mercato dei servizi di farmacocinetica dell\'Asia Pacifica è suddiviso in aziende farmaceutiche e biotecnologiche, organizzazioni di ricerca a contratto e altri. Il segmento delle organizzazioni di ricerca a contratto ha detenuto la quota di mercato più grande nel 2023.

Per paese, il mercato dei servizi di farmacocinetica dell\'Asia Pacifico è segmentato in Cina, Giappone, India, Australia, Corea del Sud e resto dell\'Asia Pacifico. Il Giappone ha dominato la quota di mercato dei servizi di farmacocinetica dell\'Asia Pacifico nel 2023.

Allucent; Certara Inc.; Charles River Laboratories International Inc; Eurofins Scientific SE; PACIFIC BIOLABS; Parexel International Corp; SGS SA; Shanghai Medicilon Inc.; e Thermo Fisher Scientific Inc. sono alcune delle aziende leader che operano nel mercato dei servizi di farmacocinetica dell\'Asia Pacifico.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics

4.1 Market Drivers

4.1.1 Rising Prevalence of Chronic and Infectious Diseases

4.1.2 Expanding Range of Application of Pharmacokinetic Studies

4.1.3 Outsourcing of Pharmacokinetics Services to CROs

4.2 Market Restraints

4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries

4.3 Market Opportunities

4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics

4.4 Future Trend

4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services

4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Asia Pacific Analysis

5.1 Asia Pacific Pharmacokinetics Services Market Overview

5.2 Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Asia Pacific Pharmacokinetics Services Market Analysis - by Drug Type

6.1 Overview

6.2 Small Molecule

6.2.1 Overview

6.2.2 Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.3 Large Molecule

6.3.1 Overview

6.3.2 Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

6.4 Vaccines

6.4.1 Overview

6.4.2 Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Pharmacokinetics Services Market Analysis - by Service Type

7.1 Overview

7.2 Pre-Clinical ADME and Human Studies

7.2.1 Overview

7.2.2 Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.3 PK/PD Analysis and Reporting

7.3.1 Overview

7.3.2 PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.4 Dosing Simulations

7.4.1 Overview

7.4.2 Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.5 Risk Analysis

7.5.1 Overview

7.5.2 Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7.6 Others

7.6.1 Overview

7.6.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Pharmacokinetics Services Market Analysis - by Therapeutic Application

8.1 Oncology

8.1.1 Overview

8.1.2 Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview

8.2.2 Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.3 Neurological Disorders

8.3.1 Overview

8.3.2 Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.4 Autoimmune Diseases

8.4.1 Overview

8.4.2 Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.5 Gynecological Disorders

8.5.1 Overview

8.5.2 Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.6 Cardiovascular Diseases

8.6.1 Overview

8.6.2 Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.7 Respiratory Disorders

8.7.1 Overview

8.7.2 Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8.8 Others

8.8.1 Overview

8.8.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Pharmacokinetics Services Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies

9.1.1 Overview

9.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.2 Contract Research Organization

9.2.1 Overview

9.2.2 Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9.3 Others

9.3.1 Overview

9.3.2 Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Asia Pacific Pharmacokinetics Services Market - Country Analysis

10.1 Asia Pacific

10.1.1 Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

10.1.1.1 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.1 Overview

10.1.1.1.2 China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.3 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.1.4 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.1.5 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.1.6 China: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.1 Overview

10.1.1.2.2 Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.3 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.2.4 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.2.5 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.2.6 Japan: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.3 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.1 Overview

10.1.1.3.2 India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.3 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.3.4 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.3.5 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.3.6 India: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.4 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.1 Overview

10.1.1.4.2 Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.4.3 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.4.4 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.4.5 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.4.6 Australia: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.5 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.1 Overview

10.1.1.5.2 South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.5.3 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.5.4 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.5.5 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.5.6 South Korea: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

10.1.1.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.1 Overview

10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Drug Type

10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Service Type

10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by Therapeutic Application

10.1.1.6.6 Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

11.1 Charles River Laboratories International Inc

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 Eurofins Scientific SE

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Certara Inc.

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.4 Parexel International Corp

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Thermo Fisher Scientific Inc.

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Allucent

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 PACIFIC BIOLABS

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 SGS SA

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Shanghai Medicilon Inc.

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms for Pharmacokinetic Services Market

 

?

List of Tables

Table 1. Asia Pacific Pharmacokinetics Services Market Segmentation

Table 2. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 3. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 4. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 5. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 6. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 7. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 8. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 9. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 10. R&D Expenditure of Indian Companies, 2018-2020 (US$ Million)

Table 11. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 12. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 13. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 14. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 15. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 16. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 17. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 18. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 19. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 20. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 21. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 22. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 23. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type

Table 24. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type

Table 25. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application

Table 26. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User

Table 27. Glossary of Terms

 

?

List of Figures

Figure 1. Asia Pacific Pharmacokinetics Services Market Segmentation, by Country

Figure 2. Asia Pacific Pharmacokinetics Services Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Asia Pacific Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

Figure 5. Asia Pacific Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)

Figure 6. Small Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 7. Large Molecule: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 8. Vaccines: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 9. Asia Pacific Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)

Figure 10. Pre-Clinical ADME and Human Studies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 11. PK/PD Analysis and Reporting: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 12. Dosing Simulations: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 13. Risk Analysis: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 14. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 15. Asia Pacific Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)

Figure 16. Oncology: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 17. Infectious Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 18. Neurological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 19. Autoimmune Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 20. Gynecological Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 21. Cardiovascular Diseases: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 22. Respiratory Disorders: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 23. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 24. Asia Pacific Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)

Figure 25. Pharmaceutical and Biotechnology Companies: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 26. Contract Research Organization: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 27. Others: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 28. Asia Pacific Pharmacokinetics Services Market - Revenue by Key Countries 2023 (US$ Million)

Figure 29. Asia Pacific Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)

Figure 30. China: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 31. Japan: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 32. India: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 33. Australia: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 34. South Korea: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

Figure 35. Rest of Asia Pacific: Asia Pacific Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

  1. Allucent
  2. Certara Inc.
  3. Charles River Laboratories International Inc
  4. Eurofins Scientific SE
  5. PACIFIC BIOLABS
  6. Parexel International Corp
  7. SGS SA
  8. Shanghai Medicilon Inc.
  9. Thermo Fisher Scientific Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pharmacokinetics services market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific pharmacokinetics services market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440